Daratumumab + bortezomib/lenalidomide/dexamethasone in patients with transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: Results of the phase 3 CEPHEUS study Meeting Abstract
| Authors: | Usmani, S. Z.; Facon, T.; Hungria, V.; Bahlis, N. J.; Venner, C. P.; Braunstein, M.; Pour, L.; Marti, J.; Basu, S.; Cohen, Y. C.; Matsumoto, M.; Suzuki, K.; Hulin, C.; Grosicki, S.; Legiec, W.; Beksac, M.; Maiolino, A.; Liu, W.; Wang, J.; Krevvata, M.; Lopez-Masi, L.; Carey, J.; Rowe, M.; Carson, R.; Zweegman, S. |
| Abstract Title: | Daratumumab + bortezomib/lenalidomide/dexamethasone in patients with transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: Results of the phase 3 CEPHEUS study |
| Meeting Title: | 21st Annual Meeting and Exposition of the International Myeloma Society |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 24 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2024 Sep 25-28 |
| Meeting Location: | Rio de Janeiro, Brazil |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2024-09-01 |
| Start Page: | S288 |
| End Page: | S289 |
| Language: | English |
| ACCESSION: | WOS:001325737900504 |
| PROVIDER: | wos |
| DOI: | 10.1016/S2152-2650(24)02344-9 |
| Notes: | Meeting Abstract: OA-63 -- Source: Wos |
